

Newbury Pharmaceuticals Secures Generic Approval for Azelastine + Fluticasone nasal spray

Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Azelastine + Fluticasone nasal spray in Norway as the first country in a Nordic registration procedure. Approvals in Sweden, Finland and Denmark are expected to follow upon finalized national reviews.

Azelastine and fluticasone combination nasal spray is used to treat an itchy or runny nose, sneezing, or other symptoms caused by seasonal hay fever (allergic rhinitis). Azelastine + Fluticasone Newbury is a generic version of Dymista nasal spray. Dymista achieved sales exceeding €21 million in the Nordics, as reported by DLMI.

“The successful approval of Azelastine + Fluticasone Newbury highlights Newbury's capability to offer a diverse and comprehensive portfolio and it is also Newbury's first marketing authorization in Finland which opens up a new market for the company” says Mr Lars Minor CEO of Newbury

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Newbury Pharmaceuticals Secures Generic Approval for Azelastine + Fluticasone nasal spray](#)